VanEck Pharmaceutical ETF
PPH
140 hedge funds and large institutions have $442M invested in VanEck Pharmaceutical ETF in 2024 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 48 increasing their positions, 35 reducing their positions, and 20 closing their positions.
37% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 35
30% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 20
6% more capital invested
Capital invested by funds: $417M → $442M (+$24.4M)
1% more funds holding
Funds holding: 138 → 140 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.61% less ownership
Funds ownership: 77.47% → 73.85% (-3.6%)
76% less call options, than puts
Call options by funds: $977K | Put options by funds: $4.03M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$15.7M |
| 2 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$13.4M |
| 3 |
Goldman Sachs
New York
|
+$8.93M |
| 4 |
FPGK
Financial Partners Group (Kansas)
Overland Park,
Kansas
|
+$8.49M |
| 5 |
BC
Bricktown Capital
Detroit,
Michigan
|
+$5.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$28.5M |
| 2 |
AC
Avestar Capital
New York
|
-$6.31M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$4.75M |
| 4 |
GIA
Gladstone Institutional Advisory
Palm Beach Gardens,
Florida
|
-$3.72M |
| 5 |
Jane Street
New York
|
-$2.34M |
PPH Hedge Fund Activity: Q2 2024 in Review
140 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q2 2024, worth a combined $442M — up 5.9% from $417M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new PPH positions and 20 closed out — a net gain of 6 holders — while 48 added to existing stakes and 35 trimmed.
The largest buyer was Thrivent Financial for Lutherans, opening a new position worth an estimated $15.7M. The largest seller was Bank of America, cutting an estimated $28.5M.
- 140 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q2 2024, up from 138 in Q1 2024.
- Funds reported $442M of VanEck Pharmaceutical ETF stock for Q2 2024, up 5.9% quarter-over-quarter.
- 26 funds opened new VanEck Pharmaceutical ETF positions in Q2 2024 and 20 closed out, a net change of +6 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q2 2024 was Thrivent Financial for Lutherans, an estimated $15.7M added.
- The largest VanEck Pharmaceutical ETF seller in Q2 2024 was Bank of America, an estimated $28.5M sold.
Based on aggregated 13F filings for Q2 2024.